Suisse_Life_Science_Group-Business-Profile

1
September 2017
Private and Conﬁdential
Business
Plan

1
Global Wellness Economy Monitor, 2017, Global Wellness Institute1
2
Suisse Life Science is a bio-tech company targeting
the estimated $3.7tn global wellness opportunity1
by using digital biological intelligence to offer
unique, personalised solutions for the integrated
management of ageing and wellbeing.
1 Global Wellness Economy Monitor, 2017, Global Wellness Institute
2

Table of Contents
Executive Summary 4
1. Opportunity 6
The health and wellness market opportunity 7
Ageing and the pursuit of beauty, health and wellness 7
Genomics driving profound change in health and wellbeing 7
Finding the Right Formula 8
Taking Control of Health and Wellbeing 8
2. Suisse Life Science 9
Unique Personalised Age-Management Solutions 10
How It Works 11
Health and Wellbeing Driven by Data and Technology 12
Early Results 12
3. Products and Services 13
Digital Biological Intelligence 14
iDDNA® Age-defying Skincare System 14
iDDNA® Age Management Health and Wellbeing System 15
Real Time Personalisation 15
4. Consumer Journey 16
Interactive Assessment 17
Onboarding 18
Personalised Solutions 18
Lifestyle Management 19
5. Behind the Scenes 20
Data Collection 21
Data analytics 22
Delivery of Personalised Solutions 23
6. Market and Competitive Environment 25
Global Wellness Economy 26
Genomics Value Chain 28
Consumer Platforms 28
Companies in Genomics and Consumer Health and Wellness Applications 29
Funding Trends 31
7. Traction 37
8. Customers and Revenues 39
Distribution 40
Pricing 43
9. Growth Strategy 44
Marketing 45
International Growth 46
10.Financial Projections 48
Sales and Expenses 49
EBITDA and Cash Flows 50
11. Team 51
Leadership Team 52
Advisory Board 54
12.Intellectual Property 56
3

Executive
Summary
As populations are ageing, the pursuit of solutions to proactively and preventively manage
the effects of ageing and to achieve holistic health and wellbeing is an increasingly large
and valuable opportunity. The rapid development of the understanding of genomics and
their implications for health, wellbeing and ageing, coupled with the increased
sophistication of technology and the growing body of data on everything from biology to
behaviour, environment and lifestyle, is enabling the development of applications that
integrate all the information available and precisely direct the user to individually
optimised solutions and approaches.
Suisse Life Science has developed exclusive technology that harnesses data from sources
ranging from the individual’s DNA to their lifestyle and interactions with the environment,
obtained through consumer electronic devices, searches the vast body of biological and
medical knowledge, and applies sophisticated algorithms, artiﬁcial intelligence and
machine learning to create precise solutions, uniquely tailored to the individual.
Suisse Life Science is using digital biological intelligence to offer unique, personalised
solutions for the integrated management of ageing and wellbeing, targeting the $3.7tn
global health and wellness opportunity.
The company’s iDDNA solutions currently include a custom age-defying skincare system,
involving a custom-designed and uniquely personalised skincare system to effectively
combat the effects of ageing, and a custom integrated age-management and health and
wellness system, involving an integrated approach to proactive and preventive health and
wellness management. These are coupled with the My iDDNA App to offer continuous
monitoring and lifestyle recommendations to the user.
Suisse Life Science offers a high-end, exclusive proposition to discerning, successful and
busy customers. The company’s solutions are offered primarily direct-to-consumer,
through online channels and through consumer platforms, such as Helix and
Sequencing.com. The company’s marketing strategy and budget are geared towards
creating signiﬁcant awareness with the end-user, through targeted advertising, press and
media coverage, and a strong online presence, achieved through SEO, content marketing
and partnerships.
4
Executive
Summary

The company has also developed successful marketing partnerships with leading exclusive
high-end member clubs, such as luxury lifestyle service Quintessentially, with whom it
expects to build its presence with the High Net Worth and Ultra High Net Worth segments.
Suisse Life Science is also building on strong previous traction with a distributor and
reseller network, including high-end anti-ageing clinics, health centres and medical spas,
among others, to develop its presence and reputation in international markets.
The company is aiming to initially pursue direct-to-consumer growth in its core market, the
UK, while developing partnerships for other markets, including the Netherlands, Taiwan,
Greece, Croatia, Kuwait, UAE, Canada, Iran. From Q4 2017-Q1 2018, Suisse Life Science
intends to expand into the US market, where it will be present online and through leading
consumer platforms. This will be closely followed by Brazil, where it is establishing a joint-
venture operation, and Asia-Paciﬁc, through exclusive distributors and resellers.
Suisse Life Science is forecasting EBITDA of £5,4M in 2018 and £20M in 2021, Cash Flows
of £3.4M in 2018 and £12.2M in 2021, and cumulative cash of £1.9M in 2018 and £27.3M in
2021.
The company is seeking to raise an investment of £1.5M to fund marketing operations,
human resources and product development.
Suisse Life Science’s leadership team is comprised of successful serial entrepreneurs,
recognised scientists and experts in bioinformatics and health and pharma focused
computer science.
The company also holds multiple valuable patents in essential processes, methods and
technologies that offer a defensible competitive advantage in delivering solutions for
personalised age management and health and wellness. 
5
“Over time I think we will probably see a closer merger of biological intelligence and
digital intelligence”
- Elon Musk
5

1. Opportunity 
6
Opportunity 01

The health and wellness market opportunity
The Global Wellness Institute estimates that the global health and
wellness market opportunity was worth US $3.7tn in 2015,
representing 5% of global economic output, based on research
reports commissioned from SRI Research and the institute’s Global
Wellness Economy Monitor. The institute also estimates that the
global market opportunity for beauty alone is US $999bn in 2015.
As consumers relentlessly pursue youth, beauty, health and
wellness, the Global Wellness Institute estimates the market has
grown 5.2% per year from 2013 to 2015, and expects this growth to
continue to 2020 in the key sectors it tracks. In particular, the
institute forecasts the global market for anti-ageing products,
technologies and services to grow from $282 billion in 2015 to
$331 billion in 2020.2
Ageing and the pursuit of beauty, health and
wellness
According to Euromonitor, as healthcare improves and high-risk
habits such as smoking are reduced, life expectancy is increasing.
The number of over-60s has risen by 34% over the last decade,
making this the fastest growing consumer segment.
This is driving growing demand for age-management solutions
and a holistic approach to health, nutrition, lifestyle and
wellbeing.3
Genomics driving profound change in health
and wellbeing
Rising awareness of the applications of genomic data for the
prediction of gene predisposition to behaviours, sensitivities and
disease development, coupled with rapidly declining costs of
genetic testing and sequencing, are leading to the rapid growth of
genomic testing and genomic data based applications for health
and wellbeing.
According to Research and Markets, the global predictive genetic
testing and consumer/wellness genomics market is anticipated to
reach USD 4.6 billion by 2025.4
Old is the New Young, 2017, Euromonitor International3
Predictive Genetic Testing and Consumer/Wellness Genomics Market by Application and Trend Analysis From4
2013 To 2025 Research and Markets, 2017
7
The Global
Health and
Wellness Market
was worth US$
3.7tn in 2015.
The number of
over-60s has
risen by 34% over
the last decade.
The
wellness
genomics market
is anticipated to
reach USD 4.6
billion by 2025

Finding the Right Formula
A UK-based study by Canadean in 2014 found that 45% of women
aged 45 and above would consider choosing a laboratory over a
department store beauty counter if it meant they could find a
product to match their skin perfectly. Of those, 54% would be
prepared to provide their own blood, hair and skin samples and
51% said they would give a DNA swab sample. 59% are prepared
to pay a premium for individual recipes.5
“Over 22% of skin care consumption by volume globally is driven
by individualism, and with the development of new technologies,
manufacturers have opportunities to take it to a whole new level.
Factors such as allergies, genetic predisposal, nutrition, climate
and exposure to the sun are all individual needs perfect for
tailoring,” explains Canadean analyst, Veronika Zhupanova.
Taking Control of Health and Wellbeing
In a survey conducted in New York, Munich and New Delhi, Bain &
Company found that 61% of people surveyed want to be able to
make more personalised choices to stay healthy and 65% agreed
that information should be simple, scientific, integrated and
personalised.6
 
Survey of 2,000 British consumers about attitudes to personalised personal care products, 2014, Canadean5
Growing Business Opportunities for Healthy Living, 2014, Bain &Company6
8
59% are
prepared to pay  
a premium for
individual
recipes
While individuals would like a
more active role in their health
and wellbeing, the multitude
varieties of skincare,
supplements, diets, exercise
regimens, and other health and
wellbeing related choices
offered to them are ultimately
confusing and are not providing
solutions that are adapted to the
individual’s unique
characteristics.
Suisse Life Science believes that
there is an opportunity to offer
skincare and broader health and
wellness solutions uniquely
tailored to an individual’s
genetic predispositions,
lifestyle, environmental, and
other influencing factors, that
are therefore highly effective.
61% want to be
able to make
more personalised
choices to stay
healthy

2. Suisse Life
Science 
9
Suisse Life
Science
02

Unique Personalised Age-Management Solutions
Suisse Life Science uses digital biological intelligence to create personalised health and
wellness solutions, offering plans and treatments speciﬁcally adapted to an individual’s
unique biomarkers, environment and lifestyle.
Suisse Life Science’s iDDNA® technology takes an individual’s unique biological, biometric,
environmental and lifestyle parameters and combines these with vast biological, genetic,
nutritional and chemical data using artiﬁcial intelligence to establish the optimal “formula”
for that individual.
10

The individual’s biomarkers, obtained through DNA sample, wrinkle analysis with AI, and a
health and lifestyle assessment, are processed to determine the individual’s genotype –
unique genetic characteristics – and phenotype – interaction of those characteristics with
the environment.
These types are then combined with real-time data collected through mobile or wearable
devices and analysed with artiﬁcial intelligence against biological, genetic, nutritional and
chemical databases to determine insights and recommendations for health and wellbeing,
uniquely tailored to the individual and taking account of the individual’s goals.
At its basic level, iDDNA® produces a personalised skincare system tailored to the
individual, to help address the visible symptoms of ageing of the skin.
At its more complete level iDDNA® produces an integrated health and wellness
management system, that includes biologically active personalised treatments,
personalised nutrition plans and dietary supplements, smart and connected lifestyle
management, and personalised ﬁtness plans, to help the individual pre-emptively manage
health and wellbeing and the effects of ageing.
How It Works
A “genetic positioning system” (“GPS”) map is created for the individual from:
- genetic and metabolic information and cross-references collected from the individual’s
DNA and from genetic databases,
- individual lifestyle and goals collected through assessments, and
- real-time lifestyle and environmental conditions detected using mobile and/or
wearable devices.
The GPS map creates a real-time, dynamic mapping of genetic predispositions and risks to
genetic and metabolic associations with nutrients, metabolites, environment and lifestyle.
This GPS map represents the body’s ecosystem, informed by biomarkers, pre-existing data
and real-time data. iDDNA® technology puts the individual in touch with their health and
wellness, querying the map as necessary, according to the individual’s goals, context and
environment.
11

Health and Wellbeing Driven by Data and Technology
Suisse Life Science is applying scientific data and technological capability to a problem
traditionally addressed through experience-based advice and informed opinion.
By capturing an individual’s unique data and combining it with the growing body of
scientific data on everything from biological reactions to lifestyle impacts, applying
proprietary algorithms and artificial intelligence to establish precise solutions to unique
profiles, iDDNA® is able to achieve outcomes that are unique and better performing for the
vast majority of people.
With iDDNA®, Suisse Life Science is positioned at the forefront of data and technology
driven solutions for health and wellbeing.
Early Results
Suisse Life Science’s solutions have been clinically tested by an independent Swiss
laboratory.
After using the products and services for 60 days, the iDDNA® programme proved the best
non-invasive treatment for 71% of customers. Skin firmness improved by 42.9%, skin
density improved by 59% and wrinkle depth shrank by 36%.
- AI and science working together to manage the root causes of ageing
- Personalised plan built from the individual customer’s biomarkers and devices
- No-drugs, biologically active treatments (cellular health).
12

3. Products and
Services 
13
Products &
Services
03

Digital Biological Intelligence
Suisse Life Science applies the latest life science, data analytics and digital technologies to
develop innovative and yet easy-to-use solutions for personalised self-care that connect
the different health and wellbeing ﬁelds of specialty.
This enables the company to offer a personalised, integrated and preventive approach to
health and wellbeing, specialising in addressing the underlying causes of ageing.
These solutions address anti-ageing and beauty, healthy nutrition and diet, ﬁtness and
sport performance, stress and sleep management, vitality, longevity and disease
prevention.
iDDNA® Age-defying Skincare System
Suisse Life Science offers a skincare system that is uniquely personalised for the individual.
A skincare formulation developed uniquely for an individual’s biomarkers, lifestyle and
environment.
The skincare system is purchased as a one-off product or as a recurring subscription. The
system is designed to offer a formulation tailored to the individual and their requirements
and therefore replaces skincare products currently being used.
 
The right ingredients.
The right formula.
Specially designed  
for me.
Perfectly curated  
for 30 or 60 days.
Skincare, nutrition,
vitamins all-in-one.
Paraben-free. No drugs.
Long-term natural
results.
Paired with AI mobile
concierge to proactively
manage pollution, UVA-
UVB, digital pollution
1414

iDDNA® Age Management Health and Wellbeing System
Suisse Life Science also offers a premium complete Health and Wellbeing System, directed
at high-performing, busy, wealthy individuals, that provides uniquely personalised plans
and treatments for skincare, nutrition, sleep and stress, fitness and preventive health, for
an integrated approach to health, wellness and age-management.
This is purchased as a recurring subscription. The system is designed to offer an integrated
approach to health and wellness, complementing other services or advisers, such as fitness
instructors, nutritionists, age-management clinics and health practitioners.
Real Time Personalisation
iDDNA systems are conceived as artificial intelligence enabled real-time assistants. They
are paired with a mobile app that collects (along with other optional wearable and health
kit devices) a range of contextual information and provides recommendations, based on
the individual’s personal, environmental and lifestyle data – a mobile digital concierge for
proactive lifestyle management. Suisse Life Science technology offers the only dynamic
application from individual genomics data and real-time contextual/environmental
information. 
The right foods. Only the
vitamins I need. The
right exercise  
for my body
Perfectly curated for 30
or 60 days. Nutrition,
vitamins, exercise all-in-
one
Non-OGM.  
No artificial ingredients
for  
healthy living.
Paired with AI mobile
concierge to proactively
manage how stress,
sleep, hormones,
pollution, temperature,
exercise affect your
lifestyle.
1515

4. Consumer
Journey 
16
Customer
Journey
04

Interactive Assessment
In the ﬁrst instance, customers are taken through an interactive assessment, online or on
the mobile, involving a biometric (age, weight, height, etc.) and lifestyle questionnaire
(ﬁtness, nutrition, sleep, etc.)
And AI-enabled wrinkle assessment.
17

Onboarding
Customers receive a home starter kit, with a membership card called the iDDNA® passport,
a swab to collect a DNA sample from saliva and a manual to help guide the DNA sample
collection as well as next steps. The iDDNA app also guides the customer through the
steps.
Collection takes only a few minutes. The DNA sample is then sent to Suisse Life Science’s
partner DNA testing lab in the IS. Customers will also take an online assessment covering
biometrics, nutrition, ﬁtness, lifestyle and other areas.
Personalised Solutions
Once the customer’s DNA is genotyped, the
iDDNA® technology develops a personalised system,
with an age-defying skincare solution or an age
management health and wellbeing solution.
Suisse Life Science sends the custom kit to the
customer - a luxurious box engraved with the
customer’s name that includes the elements of the
solution – skincare and, depending on the product
purchased, dietary supplements.  
18

The solutions are paired with a mobile app – a gateway to Suisse Life Science’s
sophisticated technology – that provides real-time contextual and environmental
information, offering a mobile digital concierge for lifestyle management.
Lifestyle Management
19
Lifestyle Management
Lifestyle ManagementLifestyle ManagementLifestyle ManagementLifestyle Management

5. Behind the
Scenes
20
Behind the
Scenes
05

Data Collection
21
DNA Analysis
Suisse Life Science gathers one-time DNA data from the customer using
a user-friendly medical device to collect oral cells, provided by DNA
Genotek, a global leader in the ﬁeld. The DNA test provides the unique
genetic blueprint of each customer, accessing the largest proprietary
direct-to-consumer genetics panel focused on healthy ageing of
850,000 biomarkers.
AI and Chatbot
The customer provides biometric (weight, height, age, etc.) and lifestyle
(exercise, sleep, nutrition, etc.) data through an interactive assessment,
online or through a chatbot.
DNA is extracted from the saliva sample using the Thermo KingFischer Flex DNA extraction
instrument, with Qiagen chemistry.
Every sample is custom genotyped in a CLIA-certiﬁed, CAP accredited US lab, on Suisse Life
Science’s proprietary panels (~820k SNPs through Affymetrix’s Precision Medicine v2 direct-
to- consumer Axiom array).
Suisse Life Science’s custom chip can detect: 1,030 SNPs (807 validated, 223 de-novo human
markers), and 175 VNTR markers.
Suisse Life Science’s patent pending application includes over 2,500 biomarkers related to
health and wellness.

Data analytics
Once the customer’s data is obtained, it is processed using Suisse Life Science’s
proprietary analytics technology, developed by its R&D team in Switzerland.
Customer DNA data is cross referenced with a database of over 5,000,000 cross-
disciplinary research publications through a proprietary algorithm called Science of [DNA]
f(x)™.
These research publications provide a scientific guidance for Suisse Life Science to design
the customer’s iDDNA®, a unique DNA-connected metabolic profile combining genetics,
biology, nutrients, metabolites, lifestyle and environmental data.
Suisse Life Science’s R&D team, in combination with advanced automated analytics
software and a number of scientific partnerships with universities and research institutions
worldwide, ensure that the research publications database is kept up-to-date, with
platform updates being pushed monthly.
Machine-learning algorithms and other artificial intelligence methodologies allow the
platform to integrate and automate the company’s expertise in areas such as biochemistry,
epigenetics, proteomics, nutrigenomics, metabolomics. The iDDNA® system is also ready to
be upgraded with additional complementary individual biological markers such as blood
work, hormone, microbiome.
Suisse Life Science’s proprietary technologies allow the company to keep up with and
make sense of the vast amounts of healthcare data forecast to double every three days by
2020, with 80% of it being unstructured.
22
Other biomarkers
Suisse Life Science technology is ready to integrate further data
sources into its analysis. As further interpretations and cross-references
become available and relevant, these will be integrated into the results.
These include sources like bloodwork, hormones, and microbiome.
Continuous Lifestyle Digital Intelligence – Real-Time
Personalisation
As the customer uses the Suisse Life Science app on their
mobile, and/or uses other third-party health kits and
wearable digital devices, the company gathers
environmental data (e.g., pollution, UVA-UVB radiation,
temperature, etc.) and self-reported data (e.g., water
consumption) and combines this with the customers’ stated
personal goals.
This data is collected continuously and enables the real-
time adjustment of recommendations to context and
environment. This also provides the company with a
platform to provide real-time feedback to customers and
engage with them continuously.
The customer’s biological age is determined through the customer’s telomere length and then
balanced with sirtuins longevity markers, ageing-related inflammatory state, NAD+ and NRF2
– cellular mediators – and lifestyle score using machine-learning age predictors.
A wide knowledge base of metabolic and epigenetic effects of natural active ingredients and
compounds and healthy lifestyle interventions is queried to design the customer’s unique
metabolic profile based on their real, biological age.
Sync my
iDDNA® with:
Health Kit
Google Fit
Fitbit
Samsung
Health

Delivery of Personalised Solutions
From the analysis, cross-referencing and individual goals, Suisse Life Science develops
tailor-made solutions for the customer.
Custom-Made Personalised Skincare
Skincare designed with the right ingredients to fit the individual’s unique
genetic predispositions and stated goals, delivered to the customer on
regular 30-day cycles. Products are delivered on a continuous basis,
with personalisation tailored to the evolving data set.
Personalised Nutrition and Fitness Plan
Nutrition, dietary supplements, and training designed for the individual,
integrating genetic predisposition information and shaped to the
individual’s specific goals.
Integrated Health and Wellness
Solutions and recommendations for weight management, stress and
sleep management, fertility and sexual performance, fitness, obesity
management, health conditions prevention, memory, mental focus and
cognitive decline prevention, hormone rebalance, and vitality and
longevity, tailored to the individual, integrating genetic predispositions –
mapping the individual’s genetic data to a pool of over 2,500+
biomarkers related to health & wellness – and continuously evolved with
real-time data.
Genes reveal crucial information
about an individual, such as
collagen generation, hyaluronic
acid production, cosmetic
allergen risk, photo-ageing risk,
predisposition to melanoma, etc.
Through analysis of the 100+
genes related to skin & hair care
(the widest DTC panel in the
word), Suisse Life Science is able
to design tailor-made skincare
solutions to each customer.
Further data gathered through
the app – e.g. sun exposure,
pollution, humidity levels,
temperature, etc. – are also taken
into account when creating the
personalised products. With the
help of this data the AI-based
concierge makes real-time
recommendations about the
customer’s lifestyle, e.g., what is
the ultimate time to spend in the
sun, what sun protection factor
to use, etc.
23

Lifestyle Recommendations
Recommendations tailored to the customers’ daily lifestyle. Integrating
the customer’s genetic predisposition, scientific data on lifestyle
interactions queried in real-time and the customers’ specific goals, the
mobile app and its AI-based concierge provides personalised and
contextualised push-recommendations.
Personalised Diet
Meal Planner
Customised
Nutraceuticals
Real-time smart food planner to
combine your favorite foods
according to scientifically-proven
approaches to keep cells younger
at a molecular level and
dynamically recreate the healthiest
food environment for you
according to your lifestyle and
environment.
The best selection of dietary
supplements, certified and
calibrated to your unique needs,
and balanced with the
micronutrients you’re already
getting from your diet and your
lifestyle. Your AI Concierge will
notify you when it's the best
moment in the day to take them.
Food Mobile
Shopping List
Restaurant
Concierge
Automatic generation of food
shopping lists to use at the market
or send via Messenger or
WhatsApp, based on your
favorites, featuring superfoods and
seasonal foods, and suggesting
nearby farmers’ markets.
Smart concierge when eating in an
international cuisine restaurant: just
select the cuisine type and your AI
concierge will show you which
dishes and servings work for you.
2424

6. Market and
Competitive
Environment 
25
Market and
Competitive
Environment
06

Global Wellness Economy
The Global Wellness Institute estimates that the global health and wellness market
opportunity was worth US $3.7tn in 2015, representing 5% of global economic output,
based on research reports commissioned from SRI Research and the institute’s Global
Wellness Economy Monitor. The institute also estimates that the global market opportunity
for beauty alone is US $999bn in 2015.
Global Wellness Economy: $3.7 trillion in 2015
Global Wellness Economy Monitor, 2017, Global Wellness Institute
As consumers relentlessly pursue youth, beauty, health and wellness, the Global Wellness
Institute estimates the market has grown 5.2% per year from 2013 to 2015, and expects this
growth to continue to 2020 in the key sectors it tracks.1 In particular, the institute forecasts
the global market for anti-ageing products, technologies and services to grow from $282
billion in 2015 to $331 billion in 2020.7
Genomics is becoming an increasingly important ﬁeld in health and wellness, in particular
in age management, as the ageing process and its visible symptoms are largely
determined by cell structure and hence DNA makeup, and in preventive health, as genetics
can provide reliable insight into the likelihood of developing certain health conditions or
reactions.
According to Research and Markets, the global predictive genetic testing and consumer/
wellness genomics market is anticipated to reach US$4.6 billion by 2025.8
Complimentary
& Alternative
Medicine  
$199b
Preventative &
Personalised
Medicine and  
Public Health
$534b
Fitness &  
Mind-Body  
$542b
Healthy Eating,  
Nutrition & 
Weight Loss
$648b
Beauty &  
Anti-Aging
$999b
$0
$100
$200
$300
$400
2015 2020
$331bn
$282bn 17%
Predictive Genetic Testing and Consumer/Wellness Genomics Market by Application and Trend Analysis From8
2013 To 2025 Research and Markets, 2017
26

Growth in genetic testing and genomics data driven applications in health and wellness is
being driven by the rapidly falling costs of genetic testing and sequencing, and by the
increasing awareness of the potential for genomics data to inform predisposition to
behaviours, sensitivities and disease development.
Source: US National Human Genome Research Institute
27
Genomics consumer
wellness applications
US$ 4.6bn
2025
0
20
40
60
80
100
'01 '02 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15 '16
Falling Fast
In the ﬁrst few years after the end of the
Human Genome Project, the cost of
genome sequencing roughly followed
Moore’s law, which predicts exponential
declines in computing costs. After 2007,
sequencing costs dropped precipitously.
The price of
sequencing a whole
human genome
hovers around $5,000
and is expected to
drop even lower.
Moore’s law for
computing costs.
Next generation
sequencers enter
the market.
Cost of
genome
sequencing.
100,000
10,000
1,000
100
10
1
Cost(thousands$US)

Genomics Value Chain
Companies in the Genomics space can broadly be characterised according to where they
intervene in the value chain – sampling and testing, sequencing, and software and
applications – and whether they are consumer wellness orientated (lifestyle, ﬁtness,
nutrition) or have medical relevance (diagnostic, preventive health).
Source: Trends Shaping the Genomics Revolution, Aug 2017, CB Insights
Consumer Platforms
As consumer interest in the health and wellness applications of genomics grows, as
genetic testing and sequencing becomes more accessible, both in terms of the information
available and cost, and as applications and interpretations for genomic data are increasing,
both in variety and in accuracy, so too are platforms to connect consumers with the
information they seek.
Companies such as 23andMe and Ancestry.com have long provided accessible genetic
testing and are developing applications ranging from the simple discovery of genetic
ancestry to understanding risk factors and causes of preventable health conditions.
Marketplace platforms are also emerging, such as Helix and Sequencing.com, that offer a
“one-stop-shop” for genomic data based applications from a variety of developers. They
provide the ability for customers to provide data once, either directly or through a given
provider of the platform, and then access (purchase) over time a range of applications that
tap into that data.
This marketplace approach is an important enabler for companies such as Suisse Life to
continue to develop the range of connections and interpretations from the data,
developing valuable new applications for consumers and/or increasing the complexity and
accuracy of the services currently provided.
Suisse Life is currently approaching both Helix and Sequencing.com in order to provide
applications and solutions through these platforms.
Medical
Relevance
Curiosity/
Wellness
Genomics PurposeGenomics “Stack"
Sample Sequence Software
28

Companies in Genomics and Consumer Health and Wellness
Applications
Suisse Life Science operates at the intersection between 1. genomic data testing and
interpretation, 2. high-end age management skincare products and solutions, and 3.
mobile health – the use of mobile devices to collect, analyse, and share health-related data.
Suisse Life Science is at the centre of these three large and dynamic markets, and faces
some competition from companies established in these markets. However, none offer the
integrated proposition.
29

Source: Companies’ Websites
Geography Vertical Genetics
Personalised
Products
Digital
Experience
Pricing
iDDNA® Worldwide 
(HQ: The UK)
Advanced
epigentics, a
panel of 1,500+
genes and 223
de novo
markers
Advanced app
with AI
concierge and
gamiﬁcation
Starting from
£699 (£299
without DNA)
GENEU® Physical
Presence in UK
Skin ✓
Diet ✗ 
Sport ✗
Testing genes
only related to
collagen
breakdown and
antioxidant
protection
- Offers an
antioxidant serum
and a serum to
optimize collagen
levels.
- However,
personalization is
limited, only based
on the levels of
active ingredients
already in the two
products
⊗
Test kit: $110  
Ultimate kit:
$2,200
(includes
DNA-test +
250ml of each
product )
DNAFit® HQ: The UK Skin ✗
Diet ✓ 
Sport ✓
Test against 45
genes
- No personalised
products
- An information and
report and
recommendations
about exercise and
nutrition based on
DNA results
⊗
$120 - $300
Habit California Skin ✗
Diet ✓ 
Sport ✗
Undertaken by a
third party,
looking at 60+
indicators
- No personalised
nutraceuticals or
supplements
- personalised meal
delivery service
- Personal nutrition
coach
A digital
dashboard
$300 for
starter kit;
Meals are
between
$7.99 and
$13.50
Pure UK and
Netherlands
Skin ✗
Diet ✓ 
Sport ✗
Focused on
disease
predisposition;
tests 50 genetic
variations
regarding diet
- Personalised
vitamin
supplements
- Builds a
personalised
nutrition and
exercise plan
- Focus on disease
prevention
A digital
dashboard
Nutrition kit:
$850  
Health and
nutrition kit:  
$1480  
Supplements:  
$105 p.m.
SKINDNA Australia,
Middle East,
and Europe
Skin ✓
Diet ✗ 
Sport ✗
Examines 16
genetic markers
related to skin
health
- No personalised
products
- Recommendations
of skin care
cosmetics
⊗
N/A; focused
at the
professional
segment, no
B2C
Pathway
Genomics
US Skin ✓
Diet ✓ 
Sport ✓
Examines
between 70 and
80 genetic
markers
depending on
the product
- No personalised
products
- Recommendations
and guidelines
directly to the
consumer or
through their
physician
⊗
$199-$349,
primarily
focused at the
professional
segment
30

Funding Trends
Funding into digital health ventures has steadily increased over the past years and is set to
be signiﬁcantly larger this year, both in terms of number of deals and amount funded.
Average amount of funding is also larger, at $18.7M.9
Source: Digital Health Funding 2017, Midterm Review, Aug 2017, RockHealth
Source: 2016 Year End Funding Report, Dec 2016, RockHealth
The most active digital health category in terms of funding was the genomics and
sequencing category, with $410M in funding.
$12.4m $10.7m $10.7m $14.8m $14.8m $13.7m $18.7m
$410M
$341M
$312M
$287M
$268M
$198M
Digital Health Funding 2017, Midterm Review, Aug 2017, RockHealth9
31

Genomics companies are attracting increasing interest, as demonstrated by rapidly
growing funding into the category.
Deal
Volume
15 21 18 34 22 13
3232

Recent Relevant Funding Deals in the Sector
DNA screening for preventive health
Raised $157.8M in 7 rounds, including $41.5M May 2014
Investors: Felicis Ventures, Founders Fund, Goldman Sachs
Genetic testing and diagnostics solutions
Raised $195M in 5 rounds, including $120M Oct 2014, IPO Feb 2015
Investors: Anya Schiess, Casdin Capital, Decheng Capital, Deerﬁeld Capital
Management, Genesys Capital, Genomic Health, J.P. Morgan Securities, OrbiMed,
Perceptive Advisors, Randy Scott, Redmile Group, Rock Springs Capital, Thomas,
McNerney & Partners, Eric Aguiar, Three Leaf Ventures, Wellington Management
Genetic testing and genomics data based applications for ancestry and predisposition
to certain health conditions
Raised $237M in 7 rounds, including $115M Jul 2015
Investors: NEA, Google, Google Ventures, Sergey Brin, J&J Development Capital,
Ilumina, Genentech
Platform for genetic data based applications
Raised $100M Aug 2015
Investors: Ilumina, Mayo Clinic Ventures, Sutter Hill Ventures, Warburg Pincus,
LaunchCapital
Genetic testing for personalised medicine
Raised $1.5M Nov 2015
Investors: SGH CAPITAL, SGH Products, TheFamily
AI for clinical genomics, for diagnostic and treatment applications
Raised $28.75M in 2 rounds, including $15M Dec 2015
Investors: Endeavour Vision, Invoke Capital Partners, Marc Coucke, Swisscom Ventures
Personalised supplementation and 360 monitoring
Raised $6.6M in 3 rounds including $5.5M Feb 2016
Investors: Illumina, Illumina Accelerator, Mehdi Maghsoodnia, Neil Hunt, Spectrum 28,
Viking Global Investors
Genomics and cell-therapy data based applications for age management and preventive
health
Raised $300M in 2 rounds, including $220M Apr 2016
Investors: Ilumina, GE Ventures, DFJ, Startup Health, Amino Capital
Data-driven personalised nutrition service
Raised $32M Oct 2016
Investors: Campbell Soup Company
Personalised skincare
Raised seed investment (undisclosed) Oct 2016
Investors: L’Oreal, Founders Factory
33

Recent M&A Deals in the Sector
Genetic testing and sequencing
Raised $42M in 2 rounds, including $30M Oct 2016
Investors: Jiangsu Simcere Pharmaceutical, Lilly Asia Ventures, Trustbridge Partners
Portable DNA sequencing devices) raised $534M in 11 rounds, including $125M Dec 2016
Investors: GT Healthcare Capital Partners, Woodford Investment Management, IP Group
plc
DNA screening for preventive health
Raised $70.55M in 2 rounds, including $65M Mar 2017
Investors: Allen & Co, AME Cloud Ventures, Andreessen Horowitz, Charles River
Associates, Data Collective, Founders Fund, Google Ventures, Innovation Endeavors,
Polaris Partners, Spectrum 28, Third Kind Venture Capital
Genetic testing for fitness and nutrition
Raised $6.6M in 4 rounds including $5M May 2017
Investors: Angels Den, Private Investors, SGHF
Personalised nutrition and insights for people to maintain normal blood sugar levels
based on their microbiome
Raised $17M in 2 rounds including $12M Jun 2017
Investors: Century Partners, French Investment Fund, Johnson & Johnson, Marius Nacht,
Mayo Clinic, Seventure Partners
Genomics data based solutions for preventive health management
Raised $150M in rounds, including $80M Aug 2017
Investors: General Catalyst, Charles River Ventures, Emerson Collective
Platform for genetic data-based applications
Currently raising series A of $10M
Acquirer Target Deal Summary
Patheon N.V. is a pharmaceutical
contract development and
manufacturing organization
headquartered in Amsterdam.
- Price: $7.2 billion
- Thermo Fisher Scientific gets
access to $40 billion contract
development and manufacturing
organization market
Core Informatics is a software
company focused on delivering
web-based LIMS software to
customers in a variety of industries.
- Price: $94 million
- Informatics firm had $10 million in
2016 revenues
- Thermo Fisher makes firm part of
its Analytical Instruments
segment
Finesse Solutions, Inc. manufactures
measurement and control solutions
for life sciences process
applications.
- Bioproduction automation
systems and software firm had
roughly $50 million in 2016
revenues
34

1011
HansaBioMed Life Sciences Ltd
offers the widest choice and
selection of products dedicated to
exosome research for Life Science
applications available on the global
market today.
- Acquisition gives Lonza access to
exosomes-based cancer assays
market
- As part of strategy, Lonza also
cuts separate deals for an equity
stake in Italian molecular
diagnostics startup Exosomics
Capsugel (United States) -
Manufactures and sells drug
capsules
- Price: $5.5 Billion in cash
(including a debt of $ 2 Billion)10
- This acquisition is in line with
Lonza’s strategy to accelerate
growth in the healthcare
continuum by opening new
opportunities.
InflammaDry and AdenoPlus
businesses owned by RPS
Diagnostics
Rapid Pathogen Screening, Inc.
(RPS) is an emerging developer,
manufacturer, and marketer of
rapid, point-of-care (POC)
diagnostic tests
- Target companies sell rapid,
lateral flow assays to detect
infectious and inflammatory eye
conditions that generate roughly
$5 million in annual revenue
- Quidel will manufacture products
in its San Diego facility
Genetic Information for Parents-to-
Be
- Good StartGenetics offers next-
generation sequencing-based
preimplantation and carrier
screening for inherited disorders
Advanced Diagnostics for Women
and Newborns
- Price: $33million
- CombiMatrix is a leader in
miscarriage analysis testing and
offers DNA-based testing for the
detection of genetic
abnormalities beyond what can
be identified through traditional
methodologies
- Invitae has focused on genetic
testing for inherited adult and
pediatric conditions. The
acquisition of Good Start and
CombiMatrix will enable it to add
reproductive health testing to its
portfolio and fulfill its aim to
become a comprehensive
genomic information company
Too Faced Cosmetics, LLC
manufactures cosmetic products for
women.
- Price: $1.45 billion11
- Status: Closed in December 2016
- Too Faced annual revenue for
2016 was $270 million
- For a label founded in 1998, this
represents a CAGR of 70%
Lonza to Acquire Capsugel to Create Leading Integrated Solutions Provider to the Global Pharma and10
Consumer Healthcare Industries, 2016, Lonza
Estée Lauder completes billion dollar takeover of Too Faced, 2017, Fashion Network11
35

Acquisitions, Alliances, Licenses and Other Strategic Transactions from the Past Month, 2017,
g2intelligence, and company websites.
121314
CeraVe - offers a range of advanced
products, speciﬁcally cleansers,
moisturizers, sunscreens, healing
ointments and a dedicated baby
line. - Price: $1.3 billion in cash12
- Status: Ongoing
- The three labels generate an
aggregate yearly revenue of $168
millionAcneFree - markets and distributes
a full range of OTC cleansers and
acne treatments in the U.S.
Ambi skin-care - distributes skincare
products formulated for the needs
of multicultural consumers
IT Cosmetics – Beauty products
created in association with leading
plastic surgeons and dermatologists
- Price: $1.2 billion13
- Status: Closed in Q3 2016
- The annual revenues of IT
Cosmetics ending in June 2016
were $182 million
Dr Ci: Labo is Japan's No. 1 Medical
Cosmetics manufactured using
natural ingredients sourced from
Japan and China
- Price: $34 million – Johnson &
Johnson bought a 19.9% stake
into Dr.Ci:Labo14
- Status: Closed
- This made Johnson & Johnson the
second largest shareholder in
Dr.Ci:Lab
Curoverse - computing and
bioinformatics company offering
software to manage, process and
share petabytes of genomic and
biomedical data as well as facilitate
AI and machine learning.
- Veritas wil expand its existing
relationship with Curoverse and
enable it to increase the
production capacity and data
management infrastructure as
well as effectively deploy AI and
machine learning on the platform,
slated to exceed 10 petabytes of
genomic data this year.
Charlotte Tilbury Beauty is a rapidly
growing hybrid skin-care, makeup
and scent brand.
- Sequoia Capital invested in
Charlotte Tillbury (undisclosed
amount)
- Leading Silicaon Valley venture
fund to become minority investor
in Charlotte Tillbury and have a
seat on the board
L’Oréal to Acquire Three U.S. Skin-Care Brands for $1.3 Billion, 2017, wwd12
L’Oréal will acquire skincare, makeup company IT Cosmetics for 1.2 bn, 2017, CosmeticsDesign-Europe13
Johnson & Johnson buys into Japanese skin care and cosmetics company Dr.Ci:Labo, 2017, CosmeticsDesign-14
Europe
36

Suisse Life Science has developed a full-scale solution (both the technology and the
operations) to deliver personalised solutions and services to customers. It makes use of
the latest epigenetics science, creating the largest direct-to-consumer lifestyle genetics
panel focused on healthy ageing (2,500+ biomarkers), as well as a database of more than
5,000,000 research publications, through machine learning and bioinformatics algorithms.
The Suisse Life Science platform is capable of interpreting relevant genetic data and
combining it in real-time with contextual, environmental and personal data collected from
other sources and devices to offer truly unique personalised solutions.
The company has built a customer base of over 1,300 customers and has geographical
presence in 12 countries through a small and fragmented distributor and reseller network.
The company has so far generated c. $2.3M in total sales, with $1.4M in 2016. The company
has managed to achieve this by building a partnership network across the world with no
direct marketing to consumers or extensive sales efforts. Due to the uniqueness of the
solutions, the majority of partners and distributors approached Suisse Life Science directly.
Over the past 12 months, the company has also introduced a number of new features such
as upgrades towards digestion discomfort, stress management, sleep management,
obesity management and sexual health, and developed new solutions, such as sports
training plans.
Suisse Life Science is an official provider of the second largest Precision Medicine initiative
in the world, the Human Longevity project. The idea behind the project is to deliver
personalised healthcare, focusing on cell therapy.
The company has patent-pending proprietary bioinformatics algorithms and has deposited
further patents recently in April 2017 on scientiﬁc methods, bioinformatics algorithms,
genetic panels and databases, which underpin the company’s solutions. The company also
holds trademarks on iDDNA® and Science of [DNA] f(x)™.
Suisse Life Science is backed by a number of high-proﬁle individuals. Institutional investors
include Tamburi Investment Partners – a listed Italian merchant bank with an excellent
track record, and Bonsai Capital, a UK and Swiss-based life sciences venture capital
investor. 
iDDNA Skincare System: iDDNA Integrated Health and Wellness System
- 1,000 customers
- US $1,000,000 in sales achieved
- 300 customers
- US $300,000 in sales achieved
38

8. Customers and
Revenues
39
Customers &
Revenues
08

Suisse Life Science’s primary target customer is a professional adult over 40, with
relatively high income and a busy lifestyle.
Suisse Life Science offers both the iDDNA Skincare System and iDDNA Age Management
System as a recurring subscription. The subscription includes access to a digital lifestyle
concierge – a mobile app that provides a range of contextual information and
recommendations, based on the individual’s environment and lifestyle.
Both systems can also be purchased as a one-time product, typically lasting 30 days.
These include DNA testing and production of a Genetic Positioning System map, with a
retail value of £599. (An entry-level skincare solution without DNA testing and Genetic
Position System map is also available for purchase).
The systems are intended to replace existing skincare expenditure and to complement
nutrition, ﬁtness and preventive health advice.
Distribution
Suisse Life Science is a Direct-to-Consumer company – it’s solutions are distributed
directly to consumers, primarily online. Own retail pop-ups and in-store points of sale will
also be considered, once the brand is established.
The company operates a distributor and reseller business alongside DTC both as a result of
initial partnerships to assist with launch and initial traction and in order to develop
strategic but remote markets, where a local presence can be better served by local
partners.
Direct-to-consumer
Suisse Life Science will primarily offer its solutions direct-to-consumer, addressing what
the company believes is the growing trend of consumers seeking ownership and control
over their own health and wellbeing and taking a closer interest in their skincare, nutrition,
ﬁtness, and preventive health.
This will be primarily through direct online sales through the company’s website. The
company may also open own stores as well as pop-stores opportunistically, and will
produce a number of promotional events throughout the year to inform customers, where
products and subscriptions will also be available for purchase.
40

Distributors and Resellers
Suisse Life Science will continue to develop its health and wellness professionals and
advisers network, as well as selectively a small number of specialist high-end retailers, to
continue to offer products through these (while subscriptions will only be available direct
to consumer).
The iDDNA systems provide specialist professionals and advisers with a high-end solution
they can offer their existing customers alongside their current services, potentially leading
to higher customer satisfaction and retention and potentially attracting new customers.
Specialist professionals and advisers include, among others:
- Anti-ageing or age-management
clinics
- Health centres
- Medical spas
- GP’s
- Nutritionists
- Personal ﬁtness instructors
- Skincare practitioners
Providers and advisers have the ability to use the iDDNA platform to offer their customers
and patients personalised solutions based on their speciﬁc characteristics, circumstances
and goals, as well as offer customers a more integrated approach to age and health
management, extending beyond their sole area of expertise.
In addition, Suisse Life Science is developing commercial arrangements with a select
number of specialist high-end retailers. Retailers currently being approached include
specialist high-end pharmacy John Bell & Croyden and high-end department store Harvey
Nichols in London, as well as Bluemercury in the US.
Marketing Partnerships
The company is also promoting its solutions
through marketing partners (affiliates), such as
high-end membership clubs and concierge
services. An example of this is the company’s
marketing partnership with exclusive concierge
service Quintessentially, running since March
2017, and through which the company has
already achieved some penetration among the
high net worth individuals target audience. In
this initial period with Quintessentially, the
company has also attracted global sales of over
£40,000. The marketing partnership with
Quintessentially is to be expanded through
Quintessentially’s white-label services – such as
HSBC Jade, Visa, Ferrari and Lamborghini’s
private member services. Marketing partners
such as Quintessentially will typically receive a
commission form sales of the order of 10%.
Genomics Platforms
The iDDNA app will also be made available for
download through reputable online platforms
concentrating on genomic data-driven apps,
such as Helix and Sequencing.com, enabling
customers to purchase or subscribe as in-app
purchases.
41

9. Growth
Strategy 
44
Growth
Strategy
09

Marketing
Suisse Life Science plans to establish the iDDNA brand through a strategy focusing on
brand awareness and customer engagement.
This will be achieved through high-end brand associations with select partners, exclusive
propositions for high-end and prominent customers, exclusive events, carefully crafted PR
campaigns aimed at engaging specialised media and inﬂuencers, and customer
engagement across social media channels.
Having achieved some initial success Suisse Life Science’s marketing effort will focus on
the end user. The objective is primarily to develop the direct to consumer market, initially
in the UK, then the US and global markets.
A smaller portion of the budget will also be allocated to global trade shows in support of
reseller and distributor sales.
Suisse Life Science expects that sales will initially be primarily driven by marketing spend.
As such a large marketing budget is planned.
Direct to Consumer Marketing will initially focus on advertorials in specialised media
(online and print) and on online/digital marketing. This will be supported by PR/media
relations investment early on.
Wholesale marketing will be a small proportion of total spend and will primarily focus on
investment in leading trade shows primarily in Europe, Asia and the US.
Additional marketing spend of c. £180,000 in 2017 and c. £ 630,000 in 2018 is planned for
concierge customer care, and marketing related travel expenses.
Expected total marketing spend across all channels:
Estimated cost of customer acquisition (per customer lead): £50 per customer lead
Estimated conversion rate (customer lead to sale): 10%, growing to 22%
Initial focus on DTC sales (purchases). Gradual emphasis on subscriptions, to reach 50%
of DTC sales.
Wholesale sales expected to build on historic sales driven by inbound enquiries. To be
boosted by additional Marketing efforts, in particular advertising spend.
2017 2018 2019 2020 2021
Marketing (£’000) 1,270 5,020 9,656 14,071 19,258
45
0
20
40
60
80
100
Sep 2017-Aug 2018 Sep 2018-Aug 2019
4%5%
73%35%
23%
60% DTC Marketing Spend UK
DTC Marketing Spend US-GLOBAL
Marketing Spend WHOLESALE
£1.1M £4.4M

Suisse Life Science is currently focused on building its presence in the UK, its primary market.
International Growth
The USA, Brazil, Russia and Asia are high growth regions for health and wellbeing and
where demand for genomics data driven applications is high and expected to grow
signiﬁcantly in the next decade. Suisse Life Science plans to develop these markets
through either a direct presence or through partnerships and distributors.
North America leads in the use of healthy lifestyle products
globally, according to the Global Wellness Institute . The15
aggregate expenditure of North America for healthy lifestyle
products was $301 billion in 2015. The USA in particular
represents an important market for genomics data based
solutions and as such represents a strategic market for Suisse
Life Science.
In the USA, the company is preparing to establish operations in
Q4 2017-Q1 2018 and will offer iDDNA direct to consumers
through its website.
The company is also targeting the US market through its marketing partnerships, such as
with Quintessentially, as well as through high-end select retailers, such as Bluemercury, and
high-end online retailers such as Net-a-Porter.
The iDDNA app will also be made available for download through reputable online
platforms concentrating on genomic data-driven apps, such as Helix and Sequencing.com,
enabling customers to purchase or subscribe as in-app purchases.
46
USA

According to a global consumer survey by Nielsen in 2015 ,16
Latin American respondents demonstrated the highest level of
preference for healthy ingredients and attributes in their diets
and lifestyle and the highest willingness to pay a premium for
health benefits in nutrition and lifestyle choices.
Brazil is the largest country in Latin America with a population
of almost 208 million, where 15% have indicated using anti-
ageing products, according to a consumer study by Statista,
compared to 21% in the UK.
Suisse Life Science is in currently seeking to establish a joint-
venture operation in Brazil with a local partner, in order to
rapidly access established distribution and local market experience, in a market where a
local operation is critical to success.
Asia-Pacific are significant markets for both beauty/anti-
ageing and for preventive health. Japan and China have the
highest per capita spending on skincare and beauty products
globally, and the beauty and personal care industry as a whole
is expecting sales of US$150 billion in Asia in 2017. China is17
predicted to be the second largest market for anti-ageing
products by 2020, behind the USA. Asia-Pacific also leads in18
the use of preventive medicine products globally. The region
was responsible for 35% of the total market for preventive
medicine products in 2016.19
Suisse Life Science is establishing business development partnerships and distributor
agreements throughout Asia-Pacific markets, in order to achieve a faster route to market
combined with intimate knowledge of preferences and local operating requirements.
In China the company is establishing an agreement with Spiren Healthcare, a reputable
French-HK company, backed by Jack Ma and Sequoia Capital China, with valuable
experience of the Chinese market.
Spiren Healthcare is focused on the VIP Anti-Ageing market in China and has developed
relationships with the Chinese healthcare industry, and a network of VIP anti-ageing clinics.
These include Yimei, a VIP anti-ageing network of 10,000 members, Shanghai Tong, a VIP
anti-ageing network of 7,000 members, CMD, a VIP anti-ageing network with a “very VIP”
positioning, and Victory Queen, VIP shopping malls, among others.
The partnership with Spiren Healthcare will be launching in February 2018.
We Are What We Eat, Healthy Eating Trends Around the World, 2015 Nielsen16
Asia: Where the Cosmetics and Skin Care Industry Reigns Supreme, 2016, asianscientist17
Transparency Market Research, 2017, Spiren Healthcare18
Dietary Supplement Market – Growth, Trends and Forecasts (2017 – 2022), 2016, mordorintelligence19
47
Brazil
Asia-
Pacific

Leadership Team
52
OMAR FOGLIADINI | Chairman and CEO
Omar is an experienced serial entrepreneur with a more than 20-
year track record in startups and health & wellness. He previously
founded and managed a European cosmetic medicine and surgery
clinics network that changed the way customers interact with
cosmetic surgery experiences, engaging for more than 13 years in
the science of ageing and deployment of cosmetic and regenerative
medicine go-to-market innovations. This venture earned him a place
in IlSole24Ore's top 20 Italian business case histories (2008).
Regularly featured in the financial press and a speaker on business
models and open innovation, he's already made Suisse Life Science
an open innovation and digitalisation case history at SUPSI
(University of Applied Sciences and Arts of Southern Switzerland).
Omar studied Economics and Business Administration at the
University of Brescia.
LAWRENCE PEMBLE | CFO
Lawrence has comprehensive experience in successfully creating,
financing and developing new businesses. He has led companies and
individual projects from acquisition to growth. Combining a strong
entrepreneurial, corporate finance and corporate governance
background, Lawrence has led numerous financing rounds, M&A
activities, IPOs and has held executive roles, up to and including
CEO, for startup and private equity backed ventures, both in private
and public capacities.
Lawrence served for more than six years in the Royal Marine
Commandos, leading front-line operations in Sierra Leone, Somalia,
Iraq and Afghanistan. Lawrence is currently studying Executive
Education at the University of Oxford’s Said Business School.
ANDREA BUSALACCHI, PhD | CHIEF HEALTH STRATEGIST
Andrea is a system nutrition and physiology expert and researcher. A
professor at the University of Catania, Palermo and Milan in Italy, he
is also a sport nutrition specialist for the Italian Olympics Committee
(CONI). He is the author of several books about preventive nutrition
and ageing prevention, including “The EPIGenetic Diet: A Recipe for
Life,” developed after three years of R&D with Suisse Life Science.
His articles have been featured in the press and medical journals.
Andrea holds a Master’s in Pharmaceutical Production Management
from MIP-Politecnico di Milano, a Master’s in Pharmaceutical
Marketing & Management from Almalaboris of Salerno, and a
Master’s in Medical Nutrition from University Politecnica Marche.

53
MARIA BEATRICE ALQUATI | COO
Maria Beatrice is a 30-year-old manager who has been in charge of
the Operations Department (operations, manufacturing, IT) since
March 2017.
Beatrice holds a BSc degree in Linguistics, an MSc degree in
Business Administration from University of Cremona and an MSc in
Law from University of Parma.
SAIF AL-DERZI | FIELD ENGAGEMENT OFFICER
With a proven track record in international business development of
pharmaceuticals, vitamins and cosmetics, Saif has been involved
with high-end, exclusive medical concierge and health private offices
pioneers such as Viavi in the UK.
Saif attained a Master of Sciences of Pharmacy from University of
Brighton.
AMIT SHARMA | BIOINFORMATICS TECH LEAD
Amit brings 10 years of experience in managing healthcare platforms
and bioinformatics data with a speciﬁc focus in cross-platforms and
mobile apps data security. Amit manages an in-house team of eight
developers. Amit holds a Master's and a BS in Computer Engineering
from RGPV University in Indore, India.
53

Advisory Board
Dr. Birep Aygün PhD
Dr. Birep Aygün is a biotechnology and genomics specialist, former Head Senior
Investigator at the European Commission DG JRC Institute for Health and Consumer
Protection-Molecular Biology and Genomics Unit. Her main duties included leading
scientific research projects and contributing to the development and the implementation
of scientific, technical and policy documents with regard to different applications of
genetic testing. Her specific public policy areas were non invasive genetic testing for
diagnostic and screening purposes and rare disease. Dr. Aygun is a keen supporter of the
democratisation of genome data and personalised medicine initiatives. She has been
actively involved in the development, validation and interpretation of genome based
biomarkers for diagnostic, predisposition and screening genetics. Her research in
molecular oncology is at the present ongoing at the Centro de Estudios Biosanitarios in
Madrid.
Dr. Birep Aygün holds a PhD in Biomolecular Sciences-Molecular Genetics from the
University of Manchester and a Master's degree in Biotechnology from METU. 
Dr. ARIANNA DI STADIO MD, PhD
Dr. Di Stadio is a plastic surgeon with a strong background in basic, translational and
clinical research on ageing and personalised medicine. She is a senior researcher at
Harvard Medical School and a member of the Committee of Experts at the National
Security Agency of Medicines and Health Products, France. She is an editor of several
peer-to-peer medical publications, and her research has been published in distinguished
medical journals.
Dr. Di Stadio holds a PhD from University “La Sapienza” of Rome.  
Dr. RICHARD N. FIRSHEIN, DO
Dr. Firshein is universally recognised as a leading authority in the fields of Integrative Anti-
AgEing Medicine and Precision Based Medicine, offering his patients a genetically
customised approach to their medical treatment. He has served as a Professor of Family
Medicine at the New York College of Osteopathic Medicine. Dr. Firshein's articles have
been featured in Harper’s Bazaar, Vogue, Self, Good Housekeeping and Men’s Health and
Bottomline Health, as well as medical journals such as Biomed and The American Society
of Clinical Oncologists. Dr. Firshein is a contributor on CNN, FOX News, CNBC, HLN, Good
Day New York, WPIX Morning Show, CBS Morning News and The Food Network.
Dr. Firshein is Board Certified in Family Medicine, trained at the University of California, Los
Angeles (UCLA).  
TAJANA TRTANJ
Tajana is a wellness expert with more than 20+ years of experience in developing
innovative wellness projects. As founder of the DNA Wellness concept in Qatar, Tajana
believes that getting older just means getting smarter. She is a former professional athlete
in competitive aerobics at the world championship level.
Tajana holds a BSc degree in Kinesiology. 
54

Dr. BALU PITCHIAH MD, MBA, MBBS, MRCPsych, CCST, MBA (OXON)
Dr. Balu is Psychotherapist and Psychological Consultant working to support founders and
startups with their emotional ﬁtness, relationship management, ultra-wellness and peak
performance coaching. A psychiatrist in Kensington and Chelsea, Dr. Balu works with NHS
multidisciplinary teams committed to helping clients achieve their full potential and enjoy
a state of physical, emotional, sexual and spiritual wellness. His particular expertise is
working with overachievers and people with Type A personalities to help them achieve
their full potential while minimising the impact of their emotional problems on their work
and family life.
Dr. Balu graduated from Stanley Medical College in Chennai, India, completed basic
psychiatric training in Sheffield, and earned an MBA from the University of Oxford.  
55

12.Intellectual
Property 
56
Intellectual
Property
12

Suisse Life Science has developed Intellectual Property, including several patents on
scientific methods, bioinformatics algorithms, genetic panels and databases, which
underpin the company’s solutions. This Intellectual Property provides the company with a
degree of exclusivity and protection over the methods and processes used in developing
its solutions.
Suisse Life Science’s patents also provide the company with a valuable, transferable asset,
as established by an independent evaluation. The patents described below have been the
object of an evaluation by an independent auditor:
1. A method for drawing up an anti-ageing and weight control programme, providing
nutrition and diet recommendations based on assessing an individual’s nutrition
choices against their genetic predispositions, identified by DNA sampling, and lifestyle
data, collected by means of a mobile device;
2. A method for identifying an individual’s sensitivity to macronutrients, providing
nutrition and diet recommendations based on assessing an individual’s sensitivity to
macronutrients against their genetic predispositions, identified by DNA sampling, and
lifestyle data, collected by means of a mobile device;
3. A method and system for planning an individual’s lifestyle, providing lifestyle
recommendations based on assessing the individual’s lifestyle options against their
genetic predispositions, identified by DNA sampling, and lifestyle data, collected by
means of a mobile device;
4. A cosmetic method for the treatment and/or prevention of the signs of skin ageing in
an individual, providing recommendations on the use of substances aimed at
controlling or preventing the signs of ageing, based on the individual’s genetic
predispositions, identified by DNA sampling, and lifestyle data, collected by means of a
mobile device.
Suisse Life Science appointed independent auditor, Prof. Riccardo Raul Bauer, with office
at Via Bergognone 13, in Milan, Italy, and listed in the Milan Register of Accountants and
Auditors, section A, under the number 1757 or 19.9.1984, to conduct an independent
evaluation of the patents with the purpose of appraising their economic value.
The auditor conducted an examination of the patents, their current and intended
applications by the company and the current and projected business income being
generated from these applications, and concluded, applying a discounted cash flow model,
that the value of the patents today is GBP 7,473,000.
In addition, Suisse Life Science, holds a number of trademarks for its brands, including for
the iDDNA brand in multiple countries, as well as for Clinicare, D & figura and related brand
images.
Suisse Life Science may seek to establish further Intellectual Property, whether applying
for further patents on methods, processes or discoveries as a result of Research and
Development activities, or applying for further trademark applications in support of the
development of commercial activities. 
57

58
Suisse Life Science Group PLC. | The Ultra-Wellness Company
suisselifescience.com 
info@suisselifescience.com 
+44 20 3096 1232

Suisse_Life_Science_Group-Business-Profile

Recommandé

Recommandé

Contenu connexe

Dernier

Dernier (20)

En vedette

En vedette (20)

Suisse_Life_Science_Group-Business-Profile